Study reveals potential new treatment for patients with melanoma
A pilot study shows that radiation therapy before immunotherapy may prolong lives of patients
Researchers at the University of Cincinnati, in partnership with Emory University, have uncovered a potentially more beneficial treatment regimen for patients with metastatic melanoma.
The results, published in the International Journal of Radiation Oncology, Biology and Physics, show that radiation before immunotherapy may prolong lives of patients with melanoma that has spread to the brain.
“Melanoma brain metastases occur in more than 50% of melanoma patients,” says corresponding author Dr. Soma Sengupta, associate professor of neurology at UC, UC Health physician and co-director of the UC Gardner Neuroscience Institute’s Brain Tumor Center. She is also the inaugural recipient of the Harold C. Schott Endowed Chair of Molecular Therapeutics.
“While both radiation therapy and ‘immune checkpoint inhibitors,’ a form of immunotherapy, are used alone or in combination for treatment of this cancer, the role of combination therapies and how these treatments could best be sequenced remains unclear,” Sengupta adds.
Immunotherapy is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function and may work by stopping or slowing the growth of cancer cells. Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T-cells to kill cancer cells.
Dr. Soma Sengupta and Daniel Krummel with members of their lab in the Vontz Center for Molecular Studies. Photo credit: Joe Fuqua / UC Creative Services
In this study, the team conducted a retrospective analysis of patients with surgically removed melanoma brain metastases who underwent treatment with either radiation, immunotherapy or a combination of both between 2010 and 2018. Of 79 specimens, only 17 samples were eligible for this study.
“Among the latter, we specifically investigated the gene expression between patients who received radiation therapy first then immune checkpoint inhibitors in comparison to the reverse,” says Daniel Pomeranz Krummel, research associate professor of neurology at UC and lead author of the paper. “We used a melanoma brain metastases animal model for validation experiments, as well.”
Pomeranz Krummel says results showed that the combination of radiation therapy and immune checkpoint inhibitors correlated to better patient survival when compared to radiation therapy alone.
“Specifically, we found that radiation followed by immunotherapy was superior compared to immunotherapy followed by radiation therapy,” he says, adding that his observation in patients was also observed in the melanoma animal model. “More genetic analysis of the tissue revealed that radiation therapy followed by immunotherapy showed that genes causing cell death signaling, usually fighting the cancer, were restricted and key indicators of inflammation were present.”
“Our study provides initial insights into the optimal sequence of treatment following surgical removal of melanoma brain metastases,” adds Sengupta, noting that this was a small sample of patients and that follow up studies are needed. “Clinical trials examining the best sequence of these treatments are necessary.”
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
This research was a collaboration with the Winship Cancer Institute at Emory University. Financial support for this research came, in part, from the National Institutes of Health-National Institute of Neurological Disorders and Stroke (NS083626), the Melanoma Fund, Winship Cancer Institute at Emory University and the Schott Chair for Molecular Therapeutics, University of Cincinnati. Researchers report no conflict of interest.
Related Stories
Coding without code: How vibe coding rewrites the rules
March 17, 2026
Vibe coding allows beginners to build sophisticated web applications with zero coding skills. Discover how vibe coding can simplify workflows and drastically boost productivity.
How the University of Cincinnati co-op program is shaping the future of work at SXSW
March 17, 2026
The University of Cincinnati served as a 2026 Workplace Track sponsor at the annual South by Southwest (SXSW) Innovation Conference March 12-18 in Austin, Texas, showcasing how co-op is redesigning the future of work.
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.